Trillium Asset Management LLC Takes $22.67 Million Position in Stryker Corporation $SYK

Posted by Brian Himes on Aug 21st, 2026

Trillium Asset Management LLC purchased a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) in the second quarter, Holdings Channel.com reports. The fund purchased 71,991 shares of the medical technology company’s stock, valued at approximately $22,666,000.

Several other large investors have also bought and sold shares of SYK. Brighton Jones LLC boosted its stake in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares in the last quarter. Schnieders Capital Management LLC. acquired a new position in Stryker during the 2nd quarter worth approximately $205,000. Marshall Wace LLP increased its position in Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares in the last quarter. Nebula Research & Development LLC bought a new position in Stryker in the 2nd quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC bought a new position in Stryker in the 2nd quarter valued at approximately $253,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. BMO Capital Markets began coverage on shares of Stryker in a research note on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price on the stock. UBS Group assumed coverage on Stryker in a research note on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target for the company. Sanford C. Bernstein set a $410.00 price objective on Stryker in a report on Friday, May 1st. BTIG Research reduced their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Finally, Wells Fargo & Company lowered their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Check Out Our Latest Report on Stryker

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the completion of the transaction, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. This trade represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 665,370 shares of company stock worth $216,238,501. Insiders own 4.60% of the company’s stock.

Stryker Trading Down 3.5%

Shares of NYSE SYK opened at $327.97 on Friday. The firm has a 50 day moving average price of $326.64 and a two-hundred day moving average price of $332.66. The stock has a market cap of $125.80 billion, a P/E ratio of 33.99, a price-to-earnings-growth ratio of 2.17 and a beta of 0.76. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.

Stryker (NYSE:SYK – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the business earned $3.13 earnings per share. Stryker’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. As a group, equities analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is presently 36.48%.

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.